Nature Communications (Dec 2022)
Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia
- Marie-Laure Charpignon,
- Bella Vakulenko-Lagun,
- Bang Zheng,
- Colin Magdamo,
- Bowen Su,
- Kyle Evans,
- Steve Rodriguez,
- Artem Sokolov,
- Sarah Boswell,
- Yi-Han Sheu,
- Melek Somai,
- Lefkos Middleton,
- Bradley T. Hyman,
- Rebecca A. Betensky,
- Stan N. Finkelstein,
- Roy E. Welsch,
- Ioanna Tzoulaki,
- Deborah Blacker,
- Sudeshna Das,
- Mark W. Albers
Affiliations
- Marie-Laure Charpignon
- Institute for Data, Systems, and Society, Massachusetts Institute of Technology
- Bella Vakulenko-Lagun
- Department of Statistics, University of Haifa
- Bang Zheng
- Ageing Epidemiology Research Unit, School of Public Health, Imperial College London
- Colin Magdamo
- Department of Neurology, Massachusetts General Hospital/Harvard Medical School
- Bowen Su
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London
- Kyle Evans
- Department of Neurology, Massachusetts General Hospital/Harvard Medical School
- Steve Rodriguez
- Department of Neurology, Massachusetts General Hospital/Harvard Medical School
- Artem Sokolov
- Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School
- Sarah Boswell
- Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School
- Yi-Han Sheu
- Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School
- Melek Somai
- Inception Labs, Collaborative for Health Delivery Sciences, Medical College of Wisconsin
- Lefkos Middleton
- Ageing Epidemiology Research Unit, School of Public Health, Imperial College London
- Bradley T. Hyman
- Department of Neurology, Massachusetts General Hospital/Harvard Medical School
- Rebecca A. Betensky
- Department of Biostatistics, School of Global Public Health, New York University
- Stan N. Finkelstein
- Institute for Data, Systems, and Society, Massachusetts Institute of Technology
- Roy E. Welsch
- Institute for Data, Systems, and Society, Massachusetts Institute of Technology
- Ioanna Tzoulaki
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London
- Deborah Blacker
- Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School
- Sudeshna Das
- Department of Neurology, Massachusetts General Hospital/Harvard Medical School
- Mark W. Albers
- Department of Neurology, Massachusetts General Hospital/Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-022-35157-w
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 17
Abstract
Previous observational studies of the diabetes drugs metformin vs. sulfonylureas have yielded mixed results about whether metformin reduces the risk of dementia, relative to the sulfonylureas. Here, the authors apply a novel competing risks approach to emulate dementia-related target trials in electronic health records of diabetic patients and a complementary systems pharmacology evaluation on human neural cells.
